Creo Medical Group's revenue for the
six
months ended in Dec. 2025 was $5.09 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $8.07 Mil.
Creo Medical Group's Revenue per Share for the
six
months ended in Dec. 2025 was $0.01.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02.
Warning Sign:
Creo Medical Group PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Creo Medical Group was 36.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -53.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -38.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 11 years, Creo Medical Group's highest 3-Year average Revenue per Share Growth Rate was -39.30% per year. The lowest was -58.00% per year. And the median was -53.10% per year.
Creo Medical Group (OTCPK:CMEOF) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Creo Medical Group Revenue Related Terms
Creo Medical Group Revenue Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Creo Medical Group's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Revenue distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $8.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creo Medical Group (CMEOF) has a Revenue of $8.07 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Creo Medical Group and its competitors.
Is Creo Medical Group's Revenue too high?
Creo Medical Group's current Revenue is $8.07 Mil. Overall, Creo Medical Group has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Revenue compare to ABT and SYK?
Creo Medical Group's Revenue of $8.07 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Creo Medical Group and its competitors. Creo Medical Group's current Revenue is $8.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current Revenue of $8.07 Mil. The stock's GF Value™ is $0.24, compared to a current price of $0.20 — trading 16.7% below its estimated fair value. The current Revenue is $8.07 Mil. Creo Medical Group's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current Revenue is $8.07 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.20 is trading 16.7% below its estimated GF Value™ of $0.24.
Key valuation signals for CMEOF:
Revenue: $8.07 Mil
GF Value™: $0.24 vs. price of $0.20 (16.7% below fair value)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
52GF Score
Get the complete analysis for CMEOF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
